Annual report [Section 13 and 15(d), not S-K Item 405]

Commitments and Contingencies (Details)

v3.26.1
Commitments and Contingencies (Details)
$ in Thousands
 12 Months Ended
Mar. 31, 2025
USD ($)
Jul. 19, 2022
USD ($)
Dec. 31, 2025
USD ($)
Dec. 31, 2024
USD ($)
Mar. 31, 2023
site
Other Commitments [Line Items]          
General and administration     $ 19,324 $ 37,885  
Number of sites | site         8
Linebacker License Agreements          
Other Commitments [Line Items]          
Upfront license fee   $ 50      
License agreement term (in days)   10 days      
License or royalty net revenue percentage   3.00%      
Minimum royalty   $ 250      
General and administration     0 120  
Equivir License Agreement          
Other Commitments [Line Items]          
General and administration     0 100  
BE-Smart License Agreement          
Other Commitments [Line Items]          
General and administration     $ 0 $ 170  
Collaborative arrangement, estimated market opportunity value $ 10,000,000        
BE-Smart License Agreement | Minimum          
Other Commitments [Line Items]          
Collaborative arrangement, estimated annual procedures 6,000        
BE-Smart License Agreement | Maximum          
Other Commitments [Line Items]          
Collaborative arrangement, estimated annual procedures $ 7,000        
Phase Three | Linebacker License Agreements          
Other Commitments [Line Items]          
Additional payment of fee   900      
New Drug Application | Linebacker License Agreements          
Other Commitments [Line Items]          
Additional payment of fee   $ 1,000